Medicare Enrolled
Dr. Jawan Ayer, MD
Obesity Medicine · Tampa, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ayer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ayer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ayer
Dr. Jawan Ayer is an obesity medicine specialist in Tampa, FL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ayer performed 22,888 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Ayer received a total of $85,099 from 47 pharmaceutical and/or device companies across 476 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ayer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 11% volume in FL
$85,099 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 90596 | Clear | January 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary — 2023
Medicare Utilization ↗22,888
Medicare services
Top 11% in FL for obesity medicine
Not available
Unique patients (not deduplicated)
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 5,500 | $0 | $3 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
4,526 | $10 | $30 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
3,063 | $12 | $50 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
2,324 | $0 | $2 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
2,158 | $22 | $60 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
1,743 | $1 | $5 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
875 | $49 | $120 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
819 | $69 | $106 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
798 | $1 | $5 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
480 | $2 | $6 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
278 | $93 | $160 |
| Hydromorphone injection, up to 4 mg An injection of hydromorphone, an opioid pain medication, with a dosage of up to 4 milligrams. |
203 | $3 | $6 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
110 | $94 | $159 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $107 | $245 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
18.8% high complexity
56.1% medium
25.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$85,099
Total received (2018-2024)
Avg $12,157/year across 7 years
Top 0% in FL for obesity medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
476
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$15,368
2023
$16,710
2022
$20,033
2021
$17,517
2020
$9,265
2019
$5,240
2018
$966
Payments by company (2024)
PFIZER INC.
$14,096
Lilly USA, LLC
$213
Novartis Pharmaceuticals Corporation
$155
Novo Nordisk Inc
$145
Alnylam Pharmaceuticals Inc.
$144
bluebird bio, Inc.
$108
Emmaus Medical, Inc.
$97
Menarini Silicon Biosystems, Inc.
$74
Regeneron Healthcare Solutions, Inc.
$51
PharmaEssentia USA Corporation
$49
Fennec Pharmaceuticals, Inc.
$39
BeiGene USA, Inc.
$31
GlaxoSmithKline, LLC.
$30
Daiichi Sankyo Inc.
$26
Azurity Pharmaceuticals, Inc.
$25
RECORDATI_RARE_DISEASES_INC.
$24
Aveo Pharmaceuticals, Inc.
$24
Incyte Corporation
$20
SHIELD THERAPEUTICS INC
$16
Top 3 companies account for 94.1% of 2024 payments
All-time payments by company (2018-2024) ›
Global Blood Therapeutics, Inc.
$36,249
PFIZER INC.
$28,279
Novartis Pharmaceuticals Corporation
$10,059
AstraZeneca Pharmaceuticals LP
$2,368
Emmaus Medical, Inc.
$2,166
Lilly USA, LLC
$1,698
Janssen Biotech, Inc.
$897
AVEO Pharmaceuticals, Inc.
$275
Novo Nordisk Inc
$262
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Incyte Corporation
$246
BeiGene USA, Inc.
$233
E.R. Squibb & Sons, L.L.C.
$169
Alnylam Pharmaceuticals Inc.
$166
Regeneron Healthcare Solutions, Inc.
$158
JAZZ PHARMACEUTICALS INC.
$147
SOBI, INC
$141
Stemline Therapeutics Inc.
$128
Exelixis Inc.
$127
EMD Serono, Inc.
$117
bluebird bio, Inc.
$108
GENZYME CORPORATION
$76
Menarini Silicon Biosystems, Inc.
$74
Daiichi Sankyo Inc.
$67
GlaxoSmithKline, LLC.
$50
PharmaEssentia USA Corporation
$49
Sun Pharmaceutical Industries Inc.
$48
Bayer HealthCare Pharmaceuticals Inc.
$44
Fennec Pharmaceuticals, Inc.
$39
ARRAY BIOPHARMA INC
$37
Celgene Corporation
$33
Kyowa Kirin, Inc.
$28
Pharmacosmos Therapeutics Inc.
$25
Azurity Pharmaceuticals, Inc.
$25
RECORDATI_RARE_DISEASES_INC.
$24
Aveo Pharmaceuticals, Inc.
$24
Genentech USA, Inc.
$24
Sumitomo Pharma America, Inc.
$24
Duchesnay USA Incorporated
$23
Gilead Sciences, Inc.
$22
Shield Therapeutics Inc
$22
Foundation Medicine, Inc.
$22
SHIELD THERAPEUTICS INC
$16
AbbVie, Inc.
$16
Exact Sciences Corporation
$15
Merck Sharp & Dohme Corporation
$15
Purdue Pharma L.P.
$14
Top 3 companies account for 87.6% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ADAKVEO · AMVUTTRA · Abraxane · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CALQUENCE · CHANTIX · CYRAMZA · Cabometyx · Cellsearch · Cologuard Collection Kit · DARZALEX · Doptelet · ELIQUIS · Endari · Enhertu · Erleada · FOTIVDA · FOUNDATIONONE · Fabhalta · GIVLAARI · GLEEVEC · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JADENU · JAKAFI · KEYTRUDA · KISQALI · Kadcyla · LIBTAYO · LUTATHERA · LYFGENIA · LYNPARZA · MEKINIST · Monoferric · Nubeqa · ODOMZO · OJJAARA · ONPATTRO · ORGOVYX · OXBRYTA · OXYCONTIN · Orserdu · PANHEMATIN · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Pedmark · Pomalyst · RETEVMO · Siklos · Stivarga · TABRECTA · TAGRISSO · TASIGNA · Trodelvy · VERZENIO · VIVIMUSTA · VYXEOS · Venclexta · Wegovy · YONSA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Obesity medicines in nearby ZIP areas
3
County median income
$75,011
Nearest hospital to ZIP centroid (approximate)
AdventHealth Carrollwood
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ayer is a mixed practice specialist, with above-average Medicare volume (top 11% in FL), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ayer experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Ayer performed 5,500 anti-nausea injection (ondansetron/zofran) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Ayer receive payments from pharmaceutical companies?
Yes. Dr. Ayer received a total of $85,099 from 47 companies across 476 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ayer's costs compare to other obesity medicines in Tampa?
Dr. Ayer's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ayer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Obesity Medicines in Tampa
Browse obesity medicines in Tampa ranked by procedure volume and transparency data.
Highest volume
Top Obesity Medicines in FL
Obesity medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Obesity Medicines in FL
Which FL obesity medicines receive the most from drug and device companies.
By company
Global Blood Therapeutics, Inc. Payments to Doctors
See all physicians who received payments from Global Blood Therapeutics, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology